MCPH1 Antibody

What is MCPH1 and why is it significant for research?

MCPH1 (Microcephalin 1) is a DNA damage response protein implicated in chromosome condensation, cell cycle regulation, and DNA repair. Its significance stems from its multiple cellular roles:

• Regulates chromosome condensation by interacting with Condensin II complex

• Functions in DNA damage-induced cellular responses and G2/M checkpoint control

• Plays critical roles in neurogenesis and regulation of cerebral cortex size

• Acts as a potential tumor suppressor, with reduced expression observed in various cancers

Mutations in MCPH1 cause primary microcephaly, characterized by reduced brain size and intellectual disability . This makes MCPH1 important for studying both neurological development disorders and cancer pathways.

Validating MCPH1 antibody specificity requires a multi-faceted approach:

• MCPH1 knockdown/knockout controls: Use siRNA, shRNA, or CRISPR-edited cell lines lacking MCPH1 expression to confirm signal loss in immunoassays

• Recombinant protein controls: Test antibody against purified MCPH1 protein fragments

• Western blot molecular weight verification: MCPH1 should appear around 93-105 kDa, though variant isoforms may be detected at ~66 kDa

• Cross-reactivity assessment: Test in various species if cross-reactivity is claimed (human MCPH1 antibodies have shown reactivity with mouse samples)

• Immunoprecipitation followed by mass spectrometry: For definitive validation of antibody specificity

What are the optimal Western blot conditions for detecting MCPH1?

Achieving consistent and specific MCPH1 detection requires careful optimization:

• Sample preparation: RIPA or NP-40 lysis buffers supplemented with protease inhibitors are effective for extracting MCPH1

• Protein loading: Load 30-50 μg of total protein per lane

• Expected molecular weight: Full-length MCPH1 appears at ~93-105 kDa, with possible variants at ~66 kDa

• Blocking conditions: 5% non-fat milk or 3-5% BSA in TBST for 1 hour at room temperature

• Primary antibody incubation: 1:500-1:1000 dilution in blocking buffer, overnight at 4°C

• Detection sensitivity: Enhanced chemiluminescence (ECL) systems are generally sufficient, though highly sensitive detection may be required for low abundance samples

Notably, in HepG2, CHP-100, and neuroblastoma cell lines, MCPH1 appears at approximately 105 kDa when probed with affinity-purified polyclonal antibodies .

What are the recommended protocols for MCPH1 immunohistochemistry?

For successful MCPH1 immunohistochemistry:

• Tissue fixation: 10% neutral buffered formalin is standard

• Section thickness: 4-5 μm sections are optimal

• Antigen retrieval: Heat-mediated retrieval with citrate buffer (pH 6.0) or TE buffer (pH 9.0)

  • Citrate buffer retrieval was used successfully in human testis and cerebral cortex tissue studies

• Antibody dilution: Begin with 1:50 for paraffin sections, but titrate to optimal concentration (1:20-1:200 range)

• Detection system: HRP/DAB or fluorescent secondary antibodies have been validated

• Positive control tissues: Human testis, cerebral cortex, kidney, and prostate tissues have shown reliable MCPH1 expression

How can I design effective MCPH1 knockdown experiments to study its function?

When designing MCPH1 knockdown experiments:

• siRNA approach:

  • Target the coding sequence or 3'UTR of MCPH1 mRNA

  • Use multiple siRNA sequences to confirm specificity of phenotype

  • Verify knockdown efficiency by both Western blot and RT-qPCR (>70% reduction is desirable)

• shRNA/CRISPR approach for stable knockdown/knockout:

  • Long-term studies benefit from stable MCPH1 knockdown/knockout

  • MCPH1-/- mice have been generated and display a premature chromosome condensation phenotype

  • A549 cells with MCPH1 overexpression provide a contrasting model system

• Key phenotypes to assess:

  • Premature chromosome condensation (PCC) phenotype (15% of cells typically show PCC in MCPH1-deficient cells)

  • Cell cycle distribution changes, especially in S and G2/M phases

  • Apoptotic rate (Annexin V/PI staining)

  • DNA damage repair capacity

• Rescue experiments:

  • Express siRNA-resistant MCPH1 constructs to confirm phenotype specificity

  • Domain-specific constructs can help identify functional regions (e.g., N-terminal domain rescues PCC phenotype)

How can I investigate the interaction between MCPH1 and Condensin II complex?

The MCPH1-Condensin II interaction is crucial for chromosome condensation regulation. To study this:

• Co-immunoprecipitation (Co-IP):

  • Use MCPH1 antibodies to pull down protein complexes

  • Probe for Condensin II subunits (particularly CAPG2) by Western blot

  • Reciprocal Co-IP with Condensin II subunit antibodies can confirm interaction

• Domain mapping:

  • The middle domain (residues 376-485) of MCPH1 mediates binding to the CAPG2 subunit of Condensin II

  • Truncation constructs can help define minimal interaction domains

• Cell-free assay approach:

  • Xenopus laevis egg extracts provide a powerful system for studying MCPH1 regulation of condensin II

  • Adding recombinant MCPH1 (particularly the N-terminal domain) inhibits loading of Condensin II onto chromosomes

• Functional assays:

  • Depletion of specific Condensin II subunits can rescue the PCC phenotype in MCPH1-deficient cells

  • Chromosome morphology assessment via microscopy is important as MCPH1-treated chromosomes display a "zigzag and fragile appearance"

What methodologies are best for studying MCPH1's role in cancer biology?

To investigate MCPH1's tumor suppressor functions:

• Expression analysis across cancer types:

  • MCPH1 expression is downregulated in lung cancer tissues compared to normal lung tissues

  • IHC of tissue microarrays can assess expression across multiple tumor types

• Cell proliferation assays:

  • Overexpression of MCPH1 in A549 lung cancer cells inhibits proliferation via S and G2/M phase arrest

  • Methods: MTT/MTS assays, colony formation assays, or real-time cell analysis

• Apoptosis pathway investigation:

  • Flow cytometry with Annexin V/PI staining quantifies apoptotic rate

  • Western blot analysis of apoptotic markers:

    • MCPH1 overexpression increases Bax and active caspase-3

    • MCPH1 overexpression decreases Bcl-2 levels

• Cell cycle analysis:

  • Flow cytometry with propidium iodide staining

  • MCPH1 overexpression arrests cells in S and G2/M phases

  • Key proteins to examine: cyclin A2, cyclin B1, CDK enzymes

• In vivo tumor models:

  • Xenograft models using MCPH1-overexpressing or MCPH1-knockdown cancer cells

  • MCPH1 knockout mice show genomic instability and enhanced cancer susceptibility

How can I visualize MCPH1's localization during DNA damage response?

MCPH1 relocalization following DNA damage can be visualized using:

• Immunofluorescence microscopy:

  • Treat cells with DNA damaging agents (IR, UV, etoposide)

  • Co-stain for MCPH1 and DNA damage markers (γ-H2AX, 53BP1)

  • MCPH1 is recruited to DNA double-strand breaks through its BRCT2/3 domains

  • Resolution: Use confocal or super-resolution microscopy for precise localization

• Live-cell imaging:

  • Generate GFP-tagged MCPH1 constructs for real-time visualization

  • Time-lapse imaging following laser microirradiation can track recruitment kinetics

• Chromatin fractionation:

  • Separate soluble nuclear proteins from chromatin-bound fraction

  • Western blot analysis of fractions shows MCPH1 enrichment in chromatin following damage

• Proximity ligation assay (PLA):

  • Visualize interactions between MCPH1 and DNA damage response proteins

  • Required: primary antibodies from different species against MCPH1 and interacting partners

Why might I observe multiple bands when detecting MCPH1 by Western blot?

Multiple bands in MCPH1 Western blots may represent:

• Alternative splice variants:

  • Full-length MCPH1 appears at 93-105 kDa

  • A functional isoform has been reported at ~66 kDa

  • A novel MCPH1 isoform that complements defective chromosome condensation has been documented

• Post-translational modifications:

  • Phosphorylation can cause mobility shifts

  • MCPH1 is phosphorylated during DNA damage response

• Proteolytic degradation products:

  • To minimize: Use fresh samples, maintain cold temperatures during preparation, include protease inhibitors

• Antibody cross-reactivity:

  • Confirm specificity with MCPH1 knockout/knockdown controls

  • Different antibodies may recognize specific domains or epitopes

• Technical factors:

  • Non-specific binding can occur with inadequate blocking or high antibody concentration

  • Reducing antibody concentration and extending incubation time may improve specificity

The observed molecular weight may vary from the calculated 93 kDa, with reported observations at 66 kDa and 100-105 kDa .

What are the species considerations when working with MCPH1 antibodies?

Species considerations are critical for MCPH1 research:

• Species reactivity variations:

  • Human and mouse MCPH1 share functional similarities but have important structural differences

  • Human MCPH1 (hMCPH1) has greater activity in inhibiting condensin II than mouse MCPH1 (mMCPH1)

• Cross-reactivity testing:

  • Some antibodies cross-react between human and mouse samples

  • Western blot testing with human cell lines (HeLa, L02, MDA-MB-453s) and mouse tissues has validated cross-reactivity for certain antibodies

• Functional differences between species:

  • Critical amino acid differences between human and mouse MCPH1:

    • T72R and E142K substitutions, combined with subdomain B substitution, convert mouse MCPH1 to have human-like activity

    • R66T-K136E substitutions in human MCPH1 reduce its activity to mouse-like levels

• Experimental design considerations:

  • If working with mouse models, validate antibody reactivity before proceeding

  • Consider species-specific differences when interpreting results between model systems

How can MCPH1 antibodies be used to study microcephaly patient samples?

For studying MCPH1-associated microcephaly:

• Diagnostic applications:

  • Western blot or IHC can assess MCPH1 protein expression in patient samples

  • MCPH1 mutations cause primary microcephaly with head circumference <3 standard deviations below mean

• Cellular phenotype analysis:

  • Patient-derived cells display premature chromosome condensation (PCC) in ~15% of cells

  • Nuclear morphology assessment: MCPH1-/- cells show intense DAPI staining with unstained nuclear spaces

  • Immunostaining protocols:

    • Fix cells in 4% paraformaldehyde

    • Permeabilize with 0.2% Triton X-100

    • Block with 3% BSA

    • Incubate with MCPH1 antibody (1:100-1:500)

    • Counterstain with DAPI

• Functional studies:

  • Patient-derived cells can be used to test complementation with wild-type or mutant MCPH1 constructs

  • The N-terminal domain of MCPH1 is sufficient to rescue the PCC phenotype, while the central domain helps shape metaphase chromosomes

• Genotype-phenotype correlations:

  • Correlate specific mutations (e.g., T27R, W75R) with protein expression levels and cellular phenotypes

  • Compare antibody-detected MCPH1 levels with severity of clinical presentation

What is known about MCPH1's role in cancer, and how can antibodies help investigate this connection?

MCPH1's tumor suppressor function can be studied using antibodies to:

• Assess expression levels across cancer types:

  • MCPH1 expression is downregulated in:

    • Lung cancer

    • Breast cancer

    • Endometrial cancer

    • Ovarian cancer

    • Glioblastoma

    • Oral squamous cell carcinoma

  • Technique: IHC of tissue microarrays with appropriate controls

• Investigate mechanisms of tumor suppression:

  • Cell cycle regulation:

    • MCPH1 regulates checkpoint kinases and cyclin expression

    • Overexpression arrests cells in S and G2/M phases

  • Apoptotic pathway:

    • MCPH1 influences Bcl-2/Bax ratio and activates caspase-3

    • E2F1-mediated apoptosis involves MCPH1

  • DNA repair capacity:

    • MCPH1 connects to p53 through microcephaly and cancer pathways

    • MCPH1 promotes accurate DNA repair

• Prognostic significance evaluation:

  • Correlate MCPH1 expression levels with patient survival and treatment response

  • Methods: IHC scoring of patient samples, tissue microarray analysis

• Therapeutic implications:

  • Restoration of MCPH1 expression or function could potentially inhibit uncontrolled cancer cell growth

  • MCPH1 overexpression inhibits cell proliferation and promotes apoptosis in lung cancer models

MCPH1 may function as a tumor suppressor gene, with reduced expression contributing to the development and progression of human cancers .

How does MCPH1 function at the molecular level in chromosome condensation regulation?

MCPH1 regulates chromosome condensation through:

• Direct interaction with Condensin II complex:

  • The central domain (residues 376-485) of MCPH1 interacts with CAPG2 subunit of Condensin II

  • This interaction can be detected by co-immunoprecipitation followed by Western blot

• Inhibition of Condensin II loading onto chromosomes:

  • The N-terminal domain of MCPH1 specifically inhibits Condensin II loading

  • Mechanism: MCPH1 competes for chromosomal binding sites with Condensin II

  • This can be demonstrated in Xenopus egg extract cell-free assays

• Cell cycle-dependent regulation:

  • MCPH1 deficiency leads to premature chromosome condensation in G2 phase

  • MCPH1-deficient cells also show delayed decondensation after mitosis

  • Active Cdk1 is required for the premature condensation phenotype

• MCPH1 domain functions:

  • N-terminal domain: Sufficient to rescue PCC phenotype in patient cells

  • Central domain: Plays auxiliary role in shaping metaphase chromosomes

  • BRCT domains: Involved in DNA damage response functions

• Critical residues:

  • T27R and W75R mutations identified in MCPH1 patients affect its function

  • Species-specific amino acid differences (T72R, E142K in subdomain A, plus subdomain B) affect condensin II inhibition activity

Understanding these molecular mechanisms provides insight into both microcephaly pathogenesis and chromosome biology fundamentals.